US Patent Issued to Celgene on Dec. 30 for "Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile" (California Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,510,533, issued on Dec. 30, was assigned to Celgene Corp. (Summit, N.J.).

"Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile" was invented by Maria Soraya Carrancio Anton (San Diego), Joshua Hansen (La Jolla, Calif.), Antonia Lopez-Girona (San Diego), Gang Lu (San Diego) and Lilly L. Wong (Solana Beach, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the ...